Atrial flutter
Atrial flutter is a fast heart rhythm of the atria, the upper chambers of the heart. MeSH describes rapid, irregular atrial contractions that come from a block of the electrical signal in the right atrium and a wave of signal that travels in a loop through it. MeSH sets it apart from atrial fibrillation: in typical flutter the fault lies in how the signal travels, and in fibrillation it lies in how the signal is first made. As in atrial fibrillation, the atria cannot pump blood effectively into the lower chambers.
- Condition
- In this atlas
Overview
Technical summary
MeSH D001282 (exact), last updated 2007-07-09; the text rests on its scope note. Two sources are set side by side and not reconciled: the MeSH note calls the contractions rapid and irregular, while a 2002 open-access review (PMC1564051) lists atrial flutter, as an example, among the atrial tachycardias in its group of regular supraventricular tachycardias. The general statement that a tachycardia is a heartbeat faster than normal rests on the MedlinePlus arrhythmia summary. No treatment guidance, frequency figure or trial result is recorded on this page.
Burden
No burden claims are published.
Claims and evidence
No claims are published for this condition yet.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact Evaluated for this: Dofetilide
Applies to Recipient not specified Patients with atrial fibrillation or flutter, as described in the US label of Tikosyn
Population, setting and follow-up
- Patients described in the indications section of the label: patients with atrial fibrillation or flutter of more than one week's duration who have been converted to normal sinus rhythm, and patients in atrial fibrillation or flutter for whom conversion to normal sinus rhythm is sought. The passages read do not state an age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of Tikosyn (dofetilide capsules, Pfizer Laboratories Div Pfizer Inc, application NDA020931; the version dated 2026-04-21 in openFDA) lists the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation or flutter) in patients with atrial fibrillation or flutter of more than one week's duration who have been converted to normal sinus rhythm, and the conversion of atrial fibrillation and flutter to normal sinus rhythm. It states that the medicine has not been shown to be effective when the atrial fibrillation is paroxysmal.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also says that, because the medicine can cause life-threatening ventricular arrhythmias, it should be reserved for patients whose atrial fibrillation or flutter is highly symptomatic; that is the label's statement, not the atlas's advice. Contraindications, other warnings, interactions, restricted-program requirements and dosing were not recorded. Generic dofetilide labels were not read. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Flecainide
Applies to Recipient not specified Patients with paroxysmal supraventricular tachycardia, paroxysmal atrial fibrillation or flutter, or life-threatening ventricular arrhythmias, as described in the US label of flecainide acetate tablets
Population, setting and follow-up
- Patients described in the indications section of the label: patients without structural heart disease who have paroxysmal supraventricular tachycardias or paroxysmal atrial fibrillation or flutter with disabling symptoms, and patients with documented life-threatening ventricular arrhythmias. The passages read do not state an age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of flecainide acetate tablets (Hikma Pharmaceuticals USA Inc., application ANDA076278; the version dated 2024-12-04 in openFDA) describes flecainide as an antiarrhythmic drug. For patients without structural heart disease it lists prevention of paroxysmal supraventricular tachycardias, including atrioventricular nodal reentrant tachycardia, and of paroxysmal atrial fibrillation or flutter, each when associated with disabling symptoms. It also lists prevention of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the physician's judgment are life-threatening. It states that there is no evidence from controlled trials that flecainide acetate favorably affects survival or the incidence of sudden death.Limitations. This claim records what one US generic label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label's indications section also carries usage statements on chronic atrial fibrillation and on where treatment for sustained ventricular tachycardia begins; they are not recorded here. Contraindications, other warnings, interactions, the label's pediatric statement and dosing were not recorded. The brand label (Tambocor) was not read, and openFDA lists other flecainide labels with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Propafenone
Applies to Recipient not specified Patients with paroxysmal atrial fibrillation or flutter, paroxysmal supraventricular tachycardia, or life-threatening ventricular arrhythmias, as described in the US label of propafenone hydrochloride tablets
Population, setting and follow-up
- Patients described in the indications section of the label: patients without structural heart disease who have paroxysmal atrial fibrillation or flutter, or paroxysmal supraventricular tachycardia, with disabling symptoms, and patients with documented life-threatening ventricular arrhythmias. The passages read do not state an age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of propafenone hydrochloride tablets (ANI Pharmaceuticals, Inc., application ANDA076550; the version dated 2025-09-12 in openFDA) describes propafenone as an antiarrhythmic. It lists prolonging the time to recurrence of paroxysmal atrial fibrillation or flutter, and of paroxysmal supraventricular tachycardia, each associated with disabling symptoms in patients without structural heart disease, and treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. It states that the effect of propafenone on mortality has not been determined.Limitations. This claim records what one US generic tablet label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also lists usage considerations (for example, that use in permanent atrial fibrillation has not been evaluated); those are the label's statements and are not repeated as advice. Extended-release capsule labels, which state a narrower atrial fibrillation indication, were not read. Contraindications, other warnings, interactions, the label's pediatric statement and dosing were not recorded. openFDA lists other propafenone labels with different dates, and its own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Sotalol
Applies to Recipient not specified Patients with life-threatening ventricular arrhythmias, or with highly symptomatic atrial fibrillation or flutter who are in sinus rhythm, as described in the US label of Betapace and Betapace AF
Population, setting and follow-up
- Patients described in the indications section of the label: patients with documented life-threatening ventricular arrhythmias such as sustained ventricular tachycardia, and patients with highly symptomatic atrial fibrillation or flutter who are currently in sinus rhythm. The passages read do not state an age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of Betapace and Betapace AF (sotalol hydrochloride tablets, Legacy Pharma USA, Inc., application NDA019865; the version dated 2024-12-16 in openFDA) describes the medicine as an antiarrhythmic. It lists the treatment of documented, life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia, and the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation or flutter) in patients with highly symptomatic atrial fibrillation or flutter who are currently in sinus rhythm. It states that the medicine has not been shown to enhance survival in patients with life-threatening ventricular arrhythmias.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also gives limitations of use for the atrial fibrillation indication (reserve for highly symptomatic patients); those are the label's statements and are not repeated as advice. Contraindications, other warnings, the label's pediatric statements and dosing were not recorded. The oral solution (Sotylize) and generic labels were not read. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Verapamil
Applies to Recipient not specified People for whom the US label of verapamil hydrochloride tablets lists an indication: angina, atrial flutter or fibrillation, supraventricular tachycardia, hypertension
Population, setting and follow-up
- Patients described in the indications section of the label. The label does not state an age range in the passages read.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of verapamil hydrochloride tablets, in the Actavis Pharma, Inc. version dated 2024-01-30 in openFDA, lists the medicine for angina (angina at rest, including vasospastic and unstable angina, and chronic stable angina); for arrhythmias (control of ventricular rate at rest and during stress, in association with digitalis, in patients with chronic atrial flutter or atrial fibrillation, and prophylaxis of repetitive paroxysmal supraventricular tachycardia); and for the treatment of hypertension, to lower blood pressure.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 35
Record details
- Record id
cardio:atrial-flutter- Content hash
5af3b4c775e3f5787838c344f4a9192e4e673e58f9af881638fde149bcb00417